Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis

Acta Neurologica Scandinavica

Volumn 107, Issue 6, 2003, Pages 412-418

  Iłzecka, Joanna ^a   Kocki, T ^a   Stelmasiak, Z ^a   Turski, W A ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Amyotrophic lateral sclerosis; Human; Kynurenic acid; Neurodegeneration

Indexed keywords

KYNURENIC ACID;

ADULT; AGE; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HEALTH STATUS; HEMOCONCENTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIMB; MALE; MOTOR NEURON DISEASE; NEUROPROTECTION; NEUROTOXICITY; QUANTITATIVE ANALYSIS; SEX DIFFERENCE;

AGE FACTORS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EXCITATORY AMINO ACID ANTAGONISTS; EXTREMITIES; FEMALE; HUMANS; KYNURENIC ACID; MALE; MEDULLA OBLONGATA; MIDDLE AGED; NEUROPROTECTIVE AGENTS; SEX FACTORS;

EID: 0037844896     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0404.2003.00076.x     Document Type: Article

References (52)

1. APPEL SH, STOCKTON-APPEL V, STEWART SS, KERMAN RH. Amyotrophic lateral sclerosis. Associated clinical disorders and immunological evaluations. Arch Neurol 1986;43:234-8.
2. SPENCER PS, ROY DN, LUDOLPH A, HUGON J, DWIVEDI MP, Schaumburg HH. Lathyrism: evidence for role of the neuroexcitatory aminoacid BOAA. Lancet 1986;2:1066-7.
3. SCHWARCZ R, MELDRUM B. Excitatory aminoacid antagonists provide a therapeutic approach to neurological disorders. Lancet 1985;2:140-3.
4. XU Z. Mechanism and treatment of motoneuron degeneration in ALS: what have SOD 1 mutants told us? Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:225-34.
5. LEIGH PN, MELDRUM BS. Excitotoxicity in ALS. Neurology 1996;47 (Suppl. 4):221-7.
6. LASLO P, LIPSKI J, FUNK GD. Differential expression of group I metabotropic glutamate receptors in motoneurons at low and high risk for degeneration in ALS. Neuroreport 2001;12:1903-8.
7. LASLO P, LIPSKI J, NICHOLSON LF, MILES GB, FUNK GD. GLUR2 AMPA receptor subunit expression in motoneurons at low and high risk for degeneration in amyotrophic lateral sclerosis. Exp Neurol 2001;169:461-71.
8. ARONICA E, CATANIA MV, GEURTS J, YANKAYA B, TROOST D. Imunohistochemical localization of group I and II metabotropic glutamate receptors in control and amyotrophic lateral sclerosis human spinal cord: upregulation in reactive astrocytes. Neuroscience 2001;105:509-20.
9. VAN WESTERLAAK MG, JOOSTEN EA, GRIBNAU AA, COOLS AR, BAR PR. Differential cortico-motoneuron vulnerability after chronic mitochondrial inhibition in vitro and the role of glutamate receptors. Brain Res 2001;922:243-9.
10. STONE TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacol Rev 1993;45:309-79.
11. TURSKI WA, NAKAMURA M, TODD WP, CARPENTER BK, WHETSELL WO JR, SCHWARCZ R. Identification and quantification of kynurenic acid in human brain tissue. Brain Res 1988;454:164-9.
12. MORONI F. Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. Eur J Pharmacol 1999;375:87-100.
13. VECSEI L, BEAL MF. Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats. Eur J Pharmacol 1991;196:239-46.
14. URENJAK J, OBRENOVITCH TP. Neuroprotective potency of kynurenic acid against excitotoxicity. Neuroreport 2000;11:1341-4.
15. TURSKI WA, URBANSKA E, DZIKI M, PARADA-TURSKA J, IKONOMIDOU C. Excitatory amino acid antagonists protect mice against seizures induced by bicuculline. Brain Res 1990;514:131-4.
16. WU HQ, TURSKI WA, UNGERSTEDT U, SCHWARCZ R. Systemic kainic acid administration in rats: effects on kynurenic acid production in vitro and in vivo. Exp Neurol 1991;113:47-52.
17. GERMANO IM, PITTS LH, MELDRUM BS, BARTKOWSKI HM, SIMON RP. Kynurenate inhibition of cell excitation decreases stroke size and deficits. Ann Neurol 1987;22:730-4.
18. BROOKS BR. El Escorial Word Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(Suppl.):96-107.
19. RIVIERE M, MEININGER V, ZEISSER P, MUNSAT T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 1998;55:526-8.
20. SHIBATA K. Fluorimetric micro-determination of kynurenic acid, an endogenous blocker of neurotoxicity, by high-performance liquid chromatography. J Chromatogr 1988;430:376-80.
21. DU F, SCHMIDT W, OKUNO E, KIDO R, KOHLER C, SCHWARCZ R. Localization of kynurenine aminotransferase immunoreactivity in the rat hippocampus. J Comp Neurol 1992;321:477-87.
22. SCHIFFER D, CORDERA S, CAVALLA P, MIGHELI A. Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J Neurol Sci 1996;139(Suppl.): 27-33.
23. FEENEY SJ, MCKELVIE PA, AUSTIN L et al. Presymptomatic motor neuron loss and reactive astrocytosis in the SOD1 mouse model of amyotrophic lateral sclerosis. Muscle Nerve 2001;24:1510-9.
24. BENDOTTI C, TORTAROLO M, SUCHAK SK et al. Transgenic SOD 1 G93A mice develop reduced GLT-1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. J Neurochem 2001;79:737-46.
25. BARAN H. JELLINGER K, DEECKE L. Kynurenine metabolism in Alzheimer's disease. J Neural Transm 1999;106:165-81.
26. BARAN H, CAIRNS N, LUBEC B, LUBEC G. Increased kynurenic acid levels and decreased brain kynurenine aminotransferase I in patients with Down syndrome. Life Sci 1996;58:1891-9.
27. OGAWA T, MATSON WR, BEAL MF et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992;42:1702-6.
28. BEAL MF, MATSON WR, STOREY E et al. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex. J Neurol Sci 1992;108:80-7.
29. BEAL MF, MATSON WR, SWARTZ KJ, GAMACHE PH, BIRD ED. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 1990;55:1327-39.
30. CONNICK JH, CARLA V, MORONI F, STONE TW. Increase in kynurenic acid in Huntington's disease motor cortex. J Neurochem 1989;52:985-7.
31. ROTHSTEIN JD, TSAI G, KUNCL RW et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann Neurol 1990;28:18-25.
32. ROTHSTEIN JD, MARTIN LJ, KUNCL RW. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med 1992;326:1464-8.
33. ROTHSTEIN JD, VAN KAMMEN M, LEVEY AI, MARTIN LJ, KUNCL RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann Neurol 1995;38:73-84.
34. LIN CL, BRISTOL LA, JIN L et al. Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis. Neuron 1998;20:589-602.
35. URBANSKA EM, CHMIELEWSKI M, KOCKI T, TURSKI WA. Formation of endogenous glutamatergic receptors antagonist kynurenic acid - differences between cortical and spinal cord slices. Brain Res 2000;878:210-2
36. BATTAGLIA G, RASSOULPOUR A, WU HQ et al. Some metabotropic glutamate receptor ligands reduce kynurenate synthesis in rats by intracellular inhibition of kynurenine aminotransferase II. J Neurochem 2000;75:2051-60.
37. HEYES MP, LACKNER A. Increased cerebrospinal fluid quinolinic acid, kynurenic acid, and L-kynurenine in acute septicemia. J Neurochem 1990;55:338-41.
38. HEYES MP, SAITO K, CROWLEY JS et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 1992;115:1249-73.
39. HEYES MP, BREW BJ, SAITO K et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. J Neuroimmunol 1992;40:71-80.
40. ENGELHARDT JI, APPEL SH. IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 1990:47:1210-6.
41. SMITH RG, HAMILTON S, HOFMANN F et al. Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. N Engl J Med 1992;327:1721-8.
42. SMITH RG, ALEXIANU ME, CRAWFORD G, NYORMOI O, STEFANI E, APPEL SH. Cytotoxicity of immunoglobulins from amyotrophic lateral sclerosis patients on a hybrid motoneuron cell line. Proc Natl Acad Sci USA 1994;91:3393-7.
43. FERRARI MD, ODINK J, TAPPARELLI C, Van Kempen GM, Pennings EJ, Bruyn GW. Serotonin metabolism in migraine. Neurology 1989;39:1239-42
44. ALAM Z, COOMBES N, WARING RH, WILLIAMS AC, STEVENTON GB. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci 1998;156:102-6.
45. SILANI V, KASARSKIS EJ, YANAGISAWA N. Nutritional management in amyotrophic lateral sclerosis: a worldwide perspective. J Neurol 1998;245(Suppl. 2):13-9.
46. DEMITRACK MA, HEYES MP, ALTEMUS M, PIGOTT TA, GOLD PW. Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: relation to clinical and biochemical variable. Biol Psychiatry 1995;37:512-20.
47. BUCHLI R, ALBERATI-GIANI D, MALHERBE P, KOHLER C, BROGER C, CESURA AM. Cloning and functional expression of a soluble form of kynurenine/alpha-aminoadipate aminotransferase from rat kidney. J Biol Chem 1995;270:29330-5.
48. GUIDETTI P, OKUNO E, SCHWARCZ R. Characterization of rat brain kynurenine aminotransferases I and II. J Neurosci Res 1997;50:457-65.
49. SHIBATA K, MUSHIAGE M, KONDO T, HAYAKAWA T, TSUGE H. Effects of vitamin B6 deficiency on the conversion ratio of tryptophan to niacin. Biosci Biotechnol Biochem 1995;59:2060-3.
50. GUILLEMIN GJ, SMITH DG, KERR SJ et al. Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis. Redox Rep 2000;5:108-11.
51. COZZI A, CARPENEDO R, MORONI F. Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[N-4-(nitrophenyl) thiazol-2-yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia. J Cereb Blood Flow Metab 1999;19:771-7.
52. SALVATI P, UKMAR G, DHO L et al. Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:741-52.